Changes
Click [[Gastrointestinal Endoscopy - Market and Volume analysis| here]] to go back to main page.
<br>
{|border="0" cellspacing="0" cellpadding="4" width="80%" align="center"
|
|
|
|
|-
|
|bgcolor = "#376091" colspan = "2"|<font color="#FFFFFF">'''Covidien'''</font>
|
|-
|
|bgcolor = "#C5D9F1"|'''Brief Description'''
|bgcolor = "#C5D9F1"|With more than $10 billion in annual sales and offerings that include thousands of different products and brands, Covidien is one of the top players in the medical device industry. The company supplies health care providers with everything from generic pharmaceuticals and disposable medical products to diagnostic imaging contrast agents and surgical devices. Covidien has more than a dozen global manufacturing operations and markets its products in 140 countries. More than half of Covidien's sales are made in the US.
|
|-
|
|rowspan = "3"|'''Revenues'''
|2008: 9.91 billion USD
|
|-
|
|2009: 10.68 billion USD
|
|-
|
|2010: 10.43 billion USD
|
|-
|
|bgcolor = "#C5D9F1"|'''Net profit (2010)'''
|bgcolor = "#C5D9F1"| 1.63 billion USD
|
|-
|
|rowspan = "3"|'''R&D expenses'''
|2008: 341 million USD
|
|-
|
|2009: 427 million USD
|
|-
|
|2010: 447 million USD
|
|-
|
|bgcolor = "#C5D9F1"|'''Number of employees'''
|bgcolor = "#C5D9F1"|41,500
|
|-
|
|'''Year Established'''
|2009
|
|-
|
|bgcolor = "#C5D9F1"|'''Headquarters'''
|bgcolor = "#C5D9F1"|20 On Hatch Lower Hatch Street Dublin 2, Ireland
|
|-
|
|'''Key People'''
|Jose Almeida (CEO)<br>Richard Meelia (Chairman)
|
|-
|
|bgcolor = "#C5D9F1"|'''Segmental revenue breakdown (2010)'''
|bgcolor = "#C5D9F1"|Medical Devices: 64%<br>Pharmaceutical Products: 19%<br>Medical Supplies: 17%
|
|-
|
|'''Geographical revenue breakdown (2010)'''
|US: 55%<br>EMEA: 25%<br>Rest of world: 20%
|
|-
|}<br clear="all">
<br>
{|border="0" cellspacing="0" cellpadding="4" width="80%" align="center"
|
|
|
|
|-
|
|bgcolor = "#376091" colspan = "2"|<font color="#FFFFFF">'''Covidien'''</font>
|
|-
|
|bgcolor = "#C5D9F1"|'''Brief Description'''
|bgcolor = "#C5D9F1"|With more than $10 billion in annual sales and offerings that include thousands of different products and brands, Covidien is one of the top players in the medical device industry. The company supplies health care providers with everything from generic pharmaceuticals and disposable medical products to diagnostic imaging contrast agents and surgical devices. Covidien has more than a dozen global manufacturing operations and markets its products in 140 countries. More than half of Covidien's sales are made in the US.
|
|-
|
|rowspan = "3"|'''Revenues'''
|2008: 9.91 billion USD
|
|-
|
|2009: 10.68 billion USD
|
|-
|
|2010: 10.43 billion USD
|
|-
|
|bgcolor = "#C5D9F1"|'''Net profit (2010)'''
|bgcolor = "#C5D9F1"| 1.63 billion USD
|
|-
|
|rowspan = "3"|'''R&D expenses'''
|2008: 341 million USD
|
|-
|
|2009: 427 million USD
|
|-
|
|2010: 447 million USD
|
|-
|
|bgcolor = "#C5D9F1"|'''Number of employees'''
|bgcolor = "#C5D9F1"|41,500
|
|-
|
|'''Year Established'''
|2009
|
|-
|
|bgcolor = "#C5D9F1"|'''Headquarters'''
|bgcolor = "#C5D9F1"|20 On Hatch Lower Hatch Street Dublin 2, Ireland
|
|-
|
|'''Key People'''
|Jose Almeida (CEO)<br>Richard Meelia (Chairman)
|
|-
|
|bgcolor = "#C5D9F1"|'''Segmental revenue breakdown (2010)'''
|bgcolor = "#C5D9F1"|Medical Devices: 64%<br>Pharmaceutical Products: 19%<br>Medical Supplies: 17%
|
|-
|
|'''Geographical revenue breakdown (2010)'''
|US: 55%<br>EMEA: 25%<br>Rest of world: 20%
|
|-
|}<br clear="all">
